Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With <i>KRAS</i> Wild-Type Tumors in Metastatic Colorectal Cancer
Dominik Paul Modest(Berliner Hochschule für Technik), Volker Heinemann(LMU Klinikum), Sebastian Stintzing(Humboldt-Universität zu Berlin), Thomas Decker, Martina Stauch, Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), S. Held(Heidelberg University), Andreas Jung(Ludwig-Maximilians-Universität München), Christoph Kahl(Klinikum Magdeburg), Salah‐Eddin Al‐Batran(Goethe University Frankfurt), Tobias Heintges(Lukaskrankenhaus), Ludwig Fischer von Weikersthal(Praxis für Hämatologie und Onkologie), Werner Scheithauer(Comprehensive Cancer Center Vienna), Markus Möhler(Heidelberg University), G. Seipelt, Christian Lerchenmüller, Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Frank Kullmann(Klinikum Weiden), Alexander Kiani(Bayreuth Medical Center)
Cited by 123
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k